Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Kennedy Institute Group Leader Dr Anjali Kusumbe who has been awarded prestigious funding from the European Research Council to investigate the link between blood vessels and tumour metastasis in bone.

Dr Anjali Kusumbe has been awarded €1.5M over five years as part of a highly competitive Starting Grant from the European Research Council. The award will support Anjali as she investigates how different types of blood vessels in the bone marrow influence the spread of cancer to bones – a common site of secondary tumours. 

Cancer spreads as cells break away from the growing tumour and move to new body sites. However, these dangerous cells often lurk in tissues for many years, before becoming reactivated to promote new tumour growth. Anjali’s research will examine how different types of blood vessels control the fate of cancer cells arriving in the bone marrow, and how this changes with age.  

Speaking of the award, Anjali said “I am really excited. This award will enable me to increase the size of my group to interrogate how ageing and the bone marrow microenvironment impacts the fate of cancer cells in bone metastasis. The strength of our project is the unique combination of cell and mouse models, advanced imaging, state-of-the-art technologies, and its interdisciplinary nature.”

Anjali joined the Kennedy Institute in July 2016 as a Kennedy Trust for Rheumatology Senior Research Fellow; she was subsequently awarded a MRC Career Development Award that supports her salary and her research into the role blood vessels during bone growth and repair and recently a John Goldman Fellowship from the Leuka Foundation that supports her research on acute myeloid leukaemia.

“Anjali has generated a lot of excitement with her innovative approaches to bone imaging. The ERC Starting Grant will give her additional resources to rapidly implement her vision and advance the Institute’s strategy. Outstanding research output depends on a supportive environment and state-of-the-art technology platforms - a condition more than met here” says Prof Michael Dustin, Director of Research, Kennedy Institute. 

 “Anjali’s research reflects the Institute’s growing interest in tissue biology” says Kennedy Institute Director, Professor Fiona Powrie. “Deciphering the interaction between immune cells and the tissue microenvironment including stem cells will be key to tackle disease-causing inflammation, fibrosis and tumorigenesis in tissues”.

The ERC Starting Grants are designed to support early-career scientists, who show outstanding potential as research leaders. The scheme is open to researchers of all nationalities across Physical Sciences and Engineering, Life Sciences, and Social Sciences and Humanities who will complete work in one of the EU Member States of Associated Countries. This grant will start in 2019.

Similar stories

Matthew Costa elected Fellow of Academy of Medical Sciences

Matthew Costa, Professor of Orthopaedic Trauma Surgery at NDORMS, has been elected a Fellow of the Academy of Medical Sciences.

COVID-19’s high blood clot risk

A recent study of patient health records found that around 1 in 100 people with COVID-19 had a venal or arterial thrombosis, with rates higher still among males, and particularly for those hospitalised.

REF 2021 results for medical research in Oxford

Today the UK Funding Bodies have published the outcomes of the recent national research assessment exercise, the Research Excellence Framework (REF) 2021.

Nurses' Day 2022

Today marks Nurses' Day 2022. This year's theme is #BestofNursing, so we chatted to some of our amazing Research Nurses about what the Best of Nursing means to them.

Rethinking pain management after injury

NDORMS researchers are to study whether a pain management treatment using cognitive behavioural therapy will improve recovery for people who have had a major leg injury.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.